IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Contacts Media Inquiries Brendan McEvoy +1 302...